Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beta/Islet Cell Regeneration Leads Diabetes Deal-Making This Decade

Executive Summary

A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.

You may also be interested in...



Ember Therapeutics Angles For Lead In ‘Brown Fat’ Therapeutics

Ember’s co-founder Bruce Spiegelman explained in the Banting Lecture at the American Diabetes Association earlier in June how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of ‘brown’ fat.

A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects

Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.

Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?

The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel